Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0476, montelukast · 9 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| Montelukast sodium | EXPERIMENTAL | Participants receive montelukast sodium for 14 days. |
| Name | Type | Description |
|---|---|---|
| MK0476, montelukast sodium / Duration of Treatment: 8 Weeks | DRUG | - |
| MK0476, montelukast sodium / Duration of Treatment: 12 Weeks | DRUG | - |
| MK0476, montelukast sodium / Duration of Treatment: 4 weeks | DRUG | - |
| Comparator: placebo / Duration of Treatment: 4 weeks | DRUG | - |
| MK0476, montelukast sodium | DRUG | - |
| Comparator: placebo | DRUG | - |
| MK0476, montelukast sodium / Duration of Treatment: 1 Year | DRUG | - |
| Comparator : fluticasone propionate / Duration of Treatment: 1 Year | DRUG | - |
| MK0476, Montelukast Sodium /Duration of Treatment : 14 Days | DRUG | - |
| MK0476, montelukast sodium / Duration of Treatment: 2 Weeks | DRUG | - |
| Comparator: placebo / Duration of Treatment: 2 Weeks | DRUG | - |
| MK-0476, montelukast sodium | DRUG | Duration of Treatment: 14 Days |
Inclusion Criteria: * Patient is currently a nonsmoker and has been a nonsmoker for at least 1 year * Patient with clinical evidence of mild/moderate asthma with or without allergic rhinitis Exclusion Criteria: * Patient has been treated in an emergency room for asthma within 4 weeks or has been ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
MK-0476, also known as montelukast, is a small molecule being studied for respiratory conditions including bronchiolitis, asthma, bronchial asthma, allergic rhinitis, and seasonal allergic rhinitis. It is currently in Phase 2 clinical development for these indications.
MK-0476 (montelukast) is being developed by Organon & Co., a company traded under the ticker symbol OGN on the stock exchange. The drug is in Phase 2 clinical development for respiratory indications.
MK-0476 (montelukast) is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials for this drug are ongoing or completed, with the most advanced completed trials being Phase 3 studies.
MK-0476 (montelukast) has been studied in clinical trials including NCT00092105, NCT00092885, and NCT00394069. These trials investigated its effects on asthma and nasal symptoms upon cat exposure, seasonal allergic rhinitis in asthma patients, and pharmacokinetics in young children with bronchiolitis.
Yes, MK-0476 is the same as montelukast. The drug is referred to by both names in clinical research, with montelukast being the generic name and MK-0476 being the investigational code name used during development.